Advances in incretin-based therapeutics for obesity
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Nature Reviews Endocrinology |
Vol/bind | 20 |
Sider (fra-til) | 67–68 |
Antal sider | 2 |
ISSN | 1759-5029 |
DOI | |
Status | Udgivet - 2024 |
ID: 377451023